Skip to content
DataLookout
Menu

TRIAGE-GSNCT06935019

TRIAGE-GS: Towards Reducing Inefficiencies Affecting Genetics Encounters Through Genome Sequencing

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2026 to Mar 2028 Show 6 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Trial status changed: Enrolling by Invitation → Active, Not Recruiting
    • Secondary endpoints: details revised at 3 of 10 entries
    • Site details revised at 2 of 2 sites
    • Collaborators: details revised at 1 of 3 entries
    • Publications: details revised at 1 of 1 entry
  2. Minor Collaborators: 2 to 3v5
  3. Minor Start date changed from estimate of May 2025 to May 14, 2025v3
  4. Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Eligibility criteria expanded, about 3 words
    • Start date: Apr 2025 to May 2025
    • Site contacts updated at 2 of 2 sites
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Determine the time-to-event (diagnosis or no active follow-up) of a GS-first (pre-geneticist evaluation) outpatient care model for rare disease compared to standard of care.
Timeframe: From date of randomization until the date of the disclosure of diagnosis/plan, up to 18 months.
Compare clinical utility of GS-first to standard of care from the perspectives of care teams.
Timeframe: 0-2 weeks after the first results disclosure to the participant/family.
Compare personal utility of GS-first to standard-of-care from the perspectives of patients, families, and care teams.
Timeframe: 0-2 weeks after the first results disclosure to the participant/family.
Assess cost-effectiveness as the incremental cost per additional case detected for GS-first compared to standard-of-care from a healthcare system payer perspective.
Timeframe: Overall during the study period (up to 18 months).

Secondary (10)

Primary diagnostic yield
Proportion of participants with dual diagnoses
Proportion of participants with partial genetic diagnoses
Proportion of participants with potential genetic diagnoses
Proportion of participants with variants of uncertain significance deemed non-contributory by the clinician
Show 5 moreShow less
Proportion of participants with secondary/incidental findings
Number of new informative HPO terms coded after evaluation by a geneticist (compared with data extracted from collateral records at the time of the referral)
Differences in amount of time/effort required for reporting genome sequencing
Number of diagnoses missed by GS in the intervention arm that were later made after geneticist evaluation
Incremental cost per unit improvement in C-GUIDE score

Arms and interventions

GS-first armExperimental

The intervention is receiving immediate clinical routine GS, prior to evaluation by a medical geneticist. Pre-test counselling will be done by a research genetic counsellor. Results of GS will be returned during the participant's first visit to Genetics Clinic by their clinical team. Subsequent clinical care (including any other clinically indicated genetic testing or workup) will be arranged by the medical geneticist in clinic.

Standard-of-care armNo intervention

The intervention group will be compared to the standard-of-care group, where evaluation by a medical geneticist in Genetics Clinic is a prerequisite to ordering of genetic testing. Clinical workups and genetic testing are ordered at the discretion of the medical geneticist involved in their clinical care, following evaluation.

Genetic: Genome sequencing pre-geneticist evaluation

Sites

2 sites in 1 country